Annals of surgical oncology · 2025
Appraisal of Residual Tumor Burden on Survival Prognosis Following Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer: A Multicenter Cohort Study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Gang, Zheng Hua-Long, Zhang Ling-Kang, Sun Yu-Qin, Li Bao-Long, Wang Yong-Hong, Wu Ju, Wu Shi-Chao, Zheng Hong-Hong, Xue Zhen, Weng Cai-Ming, Lin Jian-Xian, Tang Ji-Ao, Wang Jia-Bin, Huang Chang-Ming
Аннотация
BACKGROUND: The eighth edition American Joint Committee on Cancer (AJCC) guidelines introduced the postneoadjuvant therapy pathologic tumor, node, metastasis (ypTNM) staging system to assess gastric cancer prognosis postneoadjuvant chemotherapy; however, it overlooks other residual tumor burden aspects beyond tumor infiltration depth and positive lymph nodes.
METHODS: Data from 537 locally advanced gastric cancer patients (cT2-4NanyM0) treated with neoadjuvant chemotherapy (2010-2021) across six tertiary centers were analyzed. Prognostic factors for overall survival (OS) and recurrence-free survival (RFS) were identified using Cox regression. Reduction of carcinoembryonic antigen (ΔCEA), Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and pathologic nodal stage after neoadjuvant therapy (ypN) were incorporated into a nomogram, validated by receiver operating characteristic (ROC), C-index, calibration plots, and decision curve analyses. A novel prognostic staging system was developed on the basis of the interquartile range (IQR) of the nomogram scores.
RESULTS: The study included a training cohort of 320 patients and a validation cohort of 217. In the training cohort, multivariate Cox regression identified ypN, RECIST criteria, and ΔCEA as independent prognostic factors for OS and RFS. Nomograms for OS and RFS were developed, showing superior prognostic ability against the American Joint Committee on Cancer (AJCC) eighth edition ypTNM staging for OS (C-index: 0.792 versus 0.689; AIC: 731.268 versus 782.089; BIC: 733.737 versus 784.459) and RFS (C-index: 0.763 versus 0.679; AIC: 868.146 versus 906.772; BIC: 893.301 versus 915.299). The new system improved 3-year OS (89.7%, 64.2%, 60.2%, and 23.0%, p < 0.001) and RFS (84.3%, 79.0%, 65.1%, and 30.0%, p < 0.001) stratification over AJCC stages. Similar results were observed in the validation cohort.
CONCLUSIONS: The novel staging system, based on residual tumor burden, significantly outperforms ypTNM staging, enhancing prognostic prediction accuracy in postneoadjuvant chemotherapy patients with gastric cancer.
METHODS: Data from 537 locally advanced gastric cancer patients (cT2-4NanyM0) treated with neoadjuvant chemotherapy (2010-2021) across six tertiary centers were analyzed. Prognostic factors for overall survival (OS) and recurrence-free survival (RFS) were identified using Cox regression. Reduction of carcinoembryonic antigen (ΔCEA), Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and pathologic nodal stage after neoadjuvant therapy (ypN) were incorporated into a nomogram, validated by receiver operating characteristic (ROC), C-index, calibration plots, and decision curve analyses. A novel prognostic staging system was developed on the basis of the interquartile range (IQR) of the nomogram scores.
RESULTS: The study included a training cohort of 320 patients and a validation cohort of 217. In the training cohort, multivariate Cox regression identified ypN, RECIST criteria, and ΔCEA as independent prognostic factors for OS and RFS. Nomograms for OS and RFS were developed, showing superior prognostic ability against the American Joint Committee on Cancer (AJCC) eighth edition ypTNM staging for OS (C-index: 0.792 versus 0.689; AIC: 731.268 versus 782.089; BIC: 733.737 versus 784.459) and RFS (C-index: 0.763 versus 0.679; AIC: 868.146 versus 906.772; BIC: 893.301 versus 915.299). The new system improved 3-year OS (89.7%, 64.2%, 60.2%, and 23.0%, p < 0.001) and RFS (84.3%, 79.0%, 65.1%, and 30.0%, p < 0.001) stratification over AJCC stages. Similar results were observed in the validation cohort.
CONCLUSIONS: The novel staging system, based on residual tumor burden, significantly outperforms ypTNM staging, enhancing prognostic prediction accuracy in postneoadjuvant chemotherapy patients with gastric cancer.